Catalyst
Slingshot members are tracking this event:
Phase 3 event-driven interim analysis of VB-111 for recurrent glioblastoma, or rGBM expected sometime in mid-2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VBLT | Community voting in process | |||||
Additional Information
The GLOBE trial is designed to evaluate the efficacy, safety and tolerability of VB-111. The primary endpoint of the study is overall survival. The trial will also measure effects of treatment towards a number of additional clinical endpoints, including progression free survival (PFS), tumor response as measured by Response Assessment in Neuro-Oncology (RANO) criteria and quality of life. VBL has received Fast Track Designation for rGBM in the U.S. and orphan drug status in both the U.S. and EU. Interim data from this pivotal Phase 3 trial is expected in the second half of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 11, 2017
Occurred Source:
http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2272210
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Interim Data, Vb-111, Recurrent Glioblastoma, Rgbm, 2h 2016
